Ana Aparicio

Trials

Studies that name Ana Aparicio as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:32 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06085729 · Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

  M.D. Anderson Cancer Center · recruiting · Prostate Cancer · principal investigator
• Ph2
  NCT04592237 · Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

  M.D. Anderson Cancer Center · active not recruiting · Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma · principal investigator
• Ph1
  NCT04388852 · DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

  M.D. Anderson Cancer Center · active not recruiting · Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma · principal investigator
• Ph2
  NCT02703623 · Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

  M.D. Anderson Cancer Center · active not recruiting · Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma · principal investigator
• Ph2
  NCT00329641 · Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

  National Cancer Institute (NCI) · completed · Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
  R01CA283402 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $636,578 awarded in 2026
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Southwest Oncology Group Treatment Grant
  U10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 1985 to 2013
  Named on NCT00329641